Class I recall for Siemens bacterial infection tests

Siemens Healthcare Diagnostics' Rapid Gram Negative Combo Panels measuring bacteria to determine antibiotic treatment are under a Class I recall from the FDA. The agency said the tests, which are meant to identify certain gram negative bacteria and measure how these bacteria respond to antibiotics to help healthcare providers select the correct treatment for a patient, are inaccurately reporting certain bacteria as sensitive to certain antibiotics when they are in fact resistant. The incorrect test results relate to these antibiotics: Aztreonam, Cefotaxime, Ceftazidime, and Ceftriaxone. The tests were recalled because they can cause ineffective treatment and, in rare instances, may contribute to death. Safety Alert

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.